Exabis Library
Welcome to the e-CCO Library!
P402: Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P402: Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P403: Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for postoperative prophylaxis in Crohn’s disease after intestinal resection: a retrospective analysis from a tertiary centre
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P403: The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM